Gossamer Bio Inc at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 11:40PM GMT
Paul Choi - Goldman Sachs Group, Inc., Research Division - Equity Analyst

Okay. We'll continue with the next session. Hi, everyone. I'm Paul Choi, and I cover the small and mid-cap biotechnology sector here at Goldman Sachs. It's my pleasure to welcome Gossamer Bio for our final session of this afternoon. Joining us from the management team. To my immediate right is CMO, Richard Aranda; to my immediate left, CEO, Faheem Hasnain; and to my far left, CFO, Bryan Giraudo. What we'll do is let Faheem kick it off maybe with some introductory remarks, and then we'll get into questions. If anyone in the audience has questions along the way, please raise -- feel free to raise your hand, and we'll get a microphone to you. Also, if anyone listening in on the webcast has questions, please feel free to e-mail me, and we'll read them anonymously during the session. But with that, I'll turn it over to Faheem.

Faheem Hasnain - Gossamer Bio, Inc. - Co-Founder, CEO, President & Chairman

Yes. Thanks, Paul. So look, we're very excited about getting our Phase III off the ground.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot